Home » Topics » BioWorld Science

BioWorld Science
RSS

Second portion of Entereg NDA submitted

June 3, 2004

ViroLogic and ACLARA BioSciences to merge

June 3, 2004

PA-457 completes single-dose phase I trial

June 3, 2004

Not-approvable letter for Pozen's MT-100

June 3, 2004

Sanctura receives FDA approval

June 3, 2004

ND-1251 enters phase I for depression

June 3, 2004

Avigen to focus resources on neurological drug candidates

June 3, 2004

New phase II trial for Serostim in HARS

June 3, 2004

Successful synthesis of radiolabeled ENT-103

June 3, 2004

Preclinical safety and efficacy of chimeric yellow fever vaccine in non-human primates

June 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...